Welcome to our dedicated page for Alpha Tau Medical news (Ticker: DRTSW), a resource for investors and traders seeking the latest updates and insights on Alpha Tau Medical stock.
Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) is an Israeli clinical-stage oncology therapeutics company developing Alpha DaRT®, a radium-224–based intratumoral alpha-radiation therapy for solid tumors. The news flow around Alpha Tau centers on clinical trial progress, regulatory interactions, and operational milestones related to this technology.
Company press releases describe ongoing and planned studies of Alpha DaRT in several high-need cancer indications, including recurrent cutaneous squamous cell carcinoma, pancreatic ductal adenocarcinoma, recurrent glioblastoma multiforme, recurrent squamous cell carcinoma of the oral cavity, and locally recurrent prostate cancer. News items highlight first-in-human treatments, such as the first patient treated in a U.S. multi-center pancreatic cancer trial and the first patient treated with Alpha DaRT in the brain for recurrent glioblastoma.
Regulatory and development updates are another recurring theme. Alpha Tau reports Breakthrough Device Designation from the U.S. Food and Drug Administration for multiple indications, participation in the FDA’s Total Product Life Cycle Advisory Program for recurrent GBM, and submission of the first module of a pre-market approval application for Alpha DaRT in recurrent cutaneous squamous cell carcinoma using a modular framework. The company also discloses FDA approval of an Investigational Device Exemption for a pilot study in locally recurrent prostate cancer.
Operational and corporate news includes securing a radioactive material license for a commercial-scale Alpha DaRT manufacturing facility in New Hampshire, interim financial results, and participation in healthcare and investor conferences hosted by organizations such as J.P. Morgan, Piper Sandler, Sidoti, and Jefferies. Investors and observers following DRTS and DRTSW can use this news page to review Alpha Tau’s reported clinical milestones, regulatory steps, manufacturing preparation, and capital markets activities as they relate to the Alpha DaRT platform.
Alpha Tau (NASDAQ: DRTS) announced that the FDA approved an Investigational Device Exemption (IDE) to start a pilot study of Alpha DaRT for patients with locally recurrent prostate cancer on Dec 2, 2025. The IDE is Alpha Tau’s fifth active U.S. IDE and the U.S. trial will enroll up to 12 patients meeting biochemical recurrence by the Phoenix definition (PSA rise ≥2 ng/mL from nadir).
The study’s primary objective is to evaluate safety; secondary objectives include biochemical and clinical progression and overall survival. Management positions Alpha DaRT as a focused local salvage alpha-radiation option to potentially replace systemic androgen deprivation therapy for recurrent prostate cancer.
Alpha Tau (NASDAQ: DRTS, DRTSW) announced that CFO Raphi Levy will present at two investor conferences in December 2025: a Fireside Chat at the 37th Annual Piper Sandler Healthcare Conference on Dec 3, 2025, 1:00–1:25 PM ET in New York, and a Company Presentation at Sidoti's Year End Virtual Investor Conference on Dec 10, 2025, 11:30 AM–12:00 PM ET.
Mr. Levy will be available for 1x1 investor meetings at both events; investors should contact their Piper Sandler or Sidoti representatives to schedule.
Alpha Tau (NASDAQ: DRTS) reported a corporate update and third-quarter 2025 results highlighting clinical progress, a new U.S. radioactive material license, and strengthened cash resources. The company began U.S. pancreatic cancer treatments, expects a first U.S. GBM patient in Q4 2025, and targets completion of ReSTART and pancreatic trial recruitment by Q1 2026. The New Hampshire facility license enables onsite Alpha DaRT manufacturing with initial nameplate capacity of ~400,000 sources.
Financials: cash and short-term deposits of $75.9M and a nine-month net loss of $30.5M versus $22.3M a year earlier; R&D spend rose to $22.5M.
Alpha Tau (NASDAQ: DRTS) said CFO Raphi Levy will participate at the Jefferies Global Healthcare Conference in London on November 18–19, 2025.
Mr. Levy will take part in 1x1 investor meetings; investors should contact their Jefferies representative to schedule meetings.
Alpha Tau (Nasdaq: DRTS) received a radioactive material license from the State of New Hampshire Radiological Health Section for the first phase of its commercial-scale manufacturing facility in Hudson, New Hampshire.
The standalone building exceeds 14,000 rentable square feet and the first-phase nameplate capacity is approximately 400,000 Alpha DaRT sources for local use. The license allows the company to introduce thorium generators, equip the plant, and proceed with verification and validation steps aimed at producing Alpha DaRT treatments during 2026. Alpha DaRT is under evaluation in multiple clinical trials across several tumor types, including skin, head & neck, pancreas, lung, prostate, and brain.
Alpha Tau Medical (NASDAQ: DRTS) has announced the successful treatment of its first patient in the U.S. multi-center pancreatic cancer pilot study called IMPACT (Intratumoral Pancreatic Alpha Combination Trial). The study evaluates the company's innovative Alpha DaRT® therapy combined with chemotherapy for patients with newly diagnosed unresectable locally advanced or metastatic pancreatic adenocarcinoma.
The treatment was performed at University Cancer Centers in Houston, utilizing a minimally invasive approach under endoscopic ultrasound guidance. The trial addresses a critical medical need, as up to 87% of pancreatic cancer patients are deemed inoperable at diagnosis, with pancreatic cancer being the third leading cause of cancer-related death in the U.S., affecting approximately 66,000 new cases annually.
Alpha Tau Medical (NASDAQ: DRTS), developer of the innovative Alpha DaRT® alpha-radiation cancer therapy, announced CFO Raphi Levy's participation in five investor conferences this September 2025. The Alpha DaRT platform represents a novel approach to solid tumor treatment using localized alpha particle radiotherapy, designed to destroy tumors while preserving healthy tissue.
The conferences include the Citi Biopharma Back to School Summit, H.C. Wainwright Global Investment Conference, Oppenheimer's Targeted Radiopharmaceutical Therapies Summit, RTH & Co Radiopharma Conference, and Lytham Partners Fall Conference. The company expects key milestones and pivotal data from multiple clinical trials in 2025-2026.
Alpha Tau Medical (NASDAQ: DRTS), developer of the Alpha DaRT® cancer therapy, reported Q2 2025 financial results and corporate updates. The company received FDA approval for an IDE to conduct a U.S. pilot study for recurrent glioblastoma multiforme (GBM) treatment. Alpha Tau secured $36.9 million through strategic equity offering from Oramed and maintains a strong cash position of $83.3 million.
The company is advancing multiple U.S. clinical trials, including studies in pancreatic cancer and GBM, with patient treatments expected to begin in 2025. Their ReSTART pivotal skin cancer trial is nearing completion. The company's first phase of their Hudson, NH commercial facility is expected to be operational by early 2026. For H1 2025, Alpha Tau reported a net loss of $18.8 million ($0.25 per share), compared to $15.4 million ($0.22 per share) in H1 2024.
Alpha Tau Medical (NASDAQ: DRTS), developer of the Alpha DaRT® alpha-radiation cancer therapy, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's CFO Raphi Levy will deliver a presentation on June 5, 2025, from 1:25 to 1:55 PM ET in New York. Additionally, Mr. Levy will be available for one-on-one meetings with investors during the conference, which can be scheduled through Jefferies representatives.